Bibiliografía

1. Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer. 1997 Sep;33(10):1592-6. [PubMed]

2. Eisele A, Seystahl K, Rushing EJ, Roth P, Le Rhun E, Weller M, Gramatzki D. Venous thromboembolic events in glioblastoma patients: An epidemiological study. Eur J Neurol. 2022 Aug;29(8):2386-97. [PubMed]

3. Semrad TJ, O'Donnell R, Wun T, Chew H, Harvey D, Zhou H, White RH. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007 Apr;106(4):601-8. [PubMed]

4. Botros D, Khalafallah AM, Huq S, Dux H, Oliveira LAP, Pellegrino R, et al. Predictors and Impact of Postoperative 30-Day Readmission in Glioblastoma. Neurosurgery. 2022 Sep 1;91(3):477-84. [PubMed]

5. Constantini S, Kornowski R, Pomeranz S, Rappaport ZH. Thromboembolic phenomena in neurosurgical patients operated upon for primary and metastatic brain tumors. Acta Neurochir (Wien). 1991;109(3-4):93-7. [PubMed]

6. Cote DJ, Dawood HY, Smith TR. Venous Thromboembolism in Patients with High-Grade Glioma. Semin Thromb Hemost. 2016 Nov;42(8):877-883. [PubMed]

7. Shi S, Cheng J, Chen H, Zhang Y, Zhao Y, Wang B. Preoperative and intraoperative predictors of deep venous thrombosis in adult patients undergoing craniotomy for brain tumors: A Chinese single-center, retrospective study. Thromb Res. 2020 Dec;196:245-50. [PubMed]

8. Shi S, Cheng J, Zhao Y, Chen W. Incidence, and preoperative and intraoperative prognostic factors of deep venous thrombosis in patients with glioma following craniotomy. Clin Neurol Neurosurg. 2021 Nov;210:106998. [PubMed]

9. Zhang C, Deng Z, Yang Z, Xie J, Hou Z. A nomogram model to predict the acute venous thromboembolism risk after surgery in patients with glioma. Thromb Res. 2023 Apr;224:21-31. [PubMed]

10. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20. [PubMed]

11. Magnus N, Garnier D, Rak J. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood. 2010 Aug 5;116(5):815-8. [PubMed]

12. Magnus N, D'Asti E, Meehan B, Garnier D, Rak J. Oncogenes and the coagulation system--forces that modulate dormant and aggressive states in cancer. Thromb Res. 2014 May;133 Suppl 2:S1-9. [PubMed]

13. Sun Y, Jiang Y, Wang Y, Yu P, Su X, Song Y, et al. The epithelial-mesenchymal transition of glioma cells promotes tissue factor expression via the miR200a/ZEB1 axis. Brain Res. 2022 Mar 1;1778:147782. [PubMed]

14. Mir Seyed Nazari P, Marosi C, Moik F, Riedl J, Özer Ö, Berghoff AS, et al. Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma. Cancers (Basel). 2019;11(12):2020. [PubMed]

15. Guo Y, Zeng H, Gao C. The Role of Neutrophil Extracellular Traps in Central Nervous System Diseases and Prospects for Clinical Application. Oxid Med Cell Longev. 2021 Jul 13;2021:9931742. [PubMed]

16. Hamilton MG, Yee WH, Hull RD, Ghali WA. Venous thromboembolism prophylaxis in patients undergoing cranial neurosurgery: a systematic review and meta-analysis. Neurosurgery. 2011;68(3):571-81. [PubMed]

17. Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, et al. PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost. 2010 Sep;8(9):1959-65. [PubMed]

18. Briggs RG, Lin YH, Dadario NB, Young IM, Conner AK, Xu W, et al. Optimal timing of post-operative enoxaparin after neurosurgery: A single institution experience. Clin Neurol Neurosurg. 2021 Aug;207:106792. [PubMed]

19. Miranda S, Benhamou Y, Wells P, Carrier M. Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors. Thromb Haemost. 2019 Nov;119(11):1886-7. [PubMed]

20. Oto J, Plana E, Solmoirago MJ, Fernández-Pardo Á, Hervás D, Cana F, et al. microRNAs and Markers of Neutrophil Activation as Predictors of Early Incidental Post-Surgical Pulmonary Embolism in Patients with Intracranial Tumors. Cancers (Basel). 2020 Jun 11;12(6):1536. [PubMed]

21. Unruh D, Schwarze SR, Khoury L, Thomas C, Wu M, Chen L, et al. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol. 2016 Dec;132(6):917-930. [PubMed]

22. Wolpert F, Berghoff AS, Grossenbacher B, Lareida A, Löb R, Roth P, et al. Venous thromboembolic events in patients with brain metastases: the PICOS score. Eur J Cancer. 2020 Jul;134:75-85. [PubMed]

23. Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1993 Jun;43(6):1111-4. [PubMed]

24. Dubinski D, Won SY, Voss M, Keil F, Miesbach W, Behmanesh B, et al. Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma. Neurosurg Rev. 2022 Feb;45(1):451-7. [PubMed]

25. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008 Nov 19;300(19):2277-85. [PubMed]

26. Seidel C, Hentschel B, Simon M, Schnell O, Heese O, Tatagiba M, et al. A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network. J Neurol. 2013 Mar;260(3):847-55. [PubMed]

27. Dong J, Meng X, Li S, Chen Q, Shi L, Jiang C, Cai J. Risk of Adverse Vascular Events in Patients with Malignant Glioma Treated with Bevacizumab Plus Irinotecan: A Systematic Review and Meta-Analysis. World Neurosurg. 2019 Oct;130:e236-e243. [PubMed]

28. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40. [PubMed]

29. Norden AD, Bartolomeo J, Tanaka S, Drappatz J, Ciampa AS, Doherty LM, et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol. 2012 Jan;106(1):121-5. [PubMed]

30. Zwicker JI, Karp Leaf R, Carrier M. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. J Thromb Haemost. 2016 Sep;14(9):1736-40. [PubMed]

31. Chai-Adisaksopha C, Linkins LA, ALKindi SY, Cheah M, Crowther MA, Iorio A. Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours. Thromb Haemost. 2017 Feb 28;117(3):589-94. [PubMed]

32. Carney BJ, Uhlmann EJ, Puligandla M, Mantia C, Weber GM, Neuberg DS, Zwicker JI. Anticoagulation after intracranial hemorrhage in brain tumors: risk of recurrent hemorrhage and venous thromboembolism. Res Pract Thromb Haemost. 2020;4(5):860-5. [PubMed]

Links de interés

  • Clasificación de la Organización Mundial de la Salud (OMS) 2016 de las neoplasias del sistema nervioso central: [Enlace]
  • European Association of Neuro-Oncology: [Enlace]
  • Grupo Español de Investigación en Neurooncología (GEINO): [Enlace]
  • Guía clínica sobre manejo de la enfermedad tromboembólica de la European Society of Medical Oncology (ESMO): [Enlace]
  • Guía clínica sobre manejo de la enfermedad tromboembólica de la American Society of Clinical Oncology (ASCO): [Enlace]
  • International Brain Tumour Alliance (IBTA): [Enlace]